MedPage Today4d
Why Did a GLP-1 Receptor Agonist Fail This Parkinson's Trial?
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
MM&M3d
Hims’ Super Bowl spot for compounded GLP-1 drugs draws Senate scrutiny
Online sellers of knockoff GLP-1 drugs have seized on shortages as an opportunity to advertise a more steady, lower-cost supply of the products compared to branded versions. One such company, Hims & ...
HealthDay on MSN3d
Study Finds Exenatide Not Beneficial for Parkinson Disease
The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease seve ...
pharmaphorum5d
The Ozempic dilemma: Balancing demand, supply, and patient safety in a viral GLP-1 world
As Ozempic and other GLP-1 drugs explode in popularity ... reported seizing 369 potentially fake Ozempic pens between January and October in 2023, marking the first identification of such ...
Medscape5d
Some Patients — And Doctors — Turn to Microdosing GLP-1s
Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...
Hims & Hers faces scrutiny from senators on Super Bowl ad that ‘risks misleading' patients
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
What is compounded semaglutide and is it safe? The weight loss drugs Hims & Hers is selling, explained.
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
Is the promise of more affordable weight loss drugs too good to be true? Compounded semaglutide, explained.
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
Senators warn FDA about Super Bowl commercial believed to mislead patients
A group of Senators has warned the FDA about an ad expected to air during Sunday’s big game that they believe misleads ...